HK Stock Market Move | CSTONE PHARMA-B(02616) rose over 8% at the close. The new indication for the third phase of the anti-PD-L1 monoclonal antibody in non-small cell lung cancer was approved by the UK MHRA.

15:54 27/02/2026

Jichisheng Pharmaceutical Group-B (02616) closed up more than 8% at the end of trading, with a 6.73% increase as of the time of writing, reaching HK$6.66, with a turnover of HK$93.123 million.

CSTONE PHARMA-B(02616) rose more than 8% at the close of trading, up 6.73% to HK$6.66 at the time of writing, with a total turnover of HK$93.123 million. In terms of news, Cornerstone Pharmaceuticals previously announced that the new indication application for toripalimab has been approved by the UK MHRA, allowing the drug to be used to treat unresectable stage III NSCLC adult patients who have not experienced disease progression after platinum-based chemotherapy (CRT), have PD-L1 expression 1% on tumor cells, no sensitizing mutations in epidermal growth factor receptor (EGFR), ALK, or ROS1 gene alterations. Ping An Securities released a research report stating that Cornerstone Pharmaceuticals uses clinical development as its engine, with phase 1.0 commercialized products contributing reliable cash flow. The company's phase 2.0 projects involve innovative layouts for research and development pipelines and cutting-edge technologies. Core varieties have entered the clinical trial stage and will continue to advance candidate projects into clinical trials. The company is expected to achieve revenues of 1.95/4.64/6.33 billion yuan in the years 2025-2027 and is given a "recommended" rating for the first time coverage.

WAI CHUN BIOTEC (00660) releases its interim performance, with a net loss attributable to shareholders of HK$5.939 million, a decrease of 56.53% compared to the same period last year.

China Motor Bus (00026) released its interim results, with a post-tax loss attributable to shareholders of HK$64.404 million, representing an 88.29% increase year-on-year.

HAOHAI BIOTEC (06826) is expected to have a net profit attributable to the parent company of approximately 2.51 billion yuan in 2025, a decrease of 40.3% year-on-year.

WAI CHUN BIOTEC (00660) releases its interim performance, with a net loss attributable to shareholders of HK$5.939 million, a decrease of 56.53% compared to the same period last year.

China Motor Bus (00026) released its interim results, with a post-tax loss attributable to shareholders of HK$64.404 million, representing an 88.29% increase year-on-year.

HAOHAI BIOTEC (06826) is expected to have a net profit attributable to the parent company of approximately 2.51 billion yuan in 2025, a decrease of 40.3% year-on-year.